Skip to Content

Infigratinib FDA Approval Status

FDA Approved: No
Generic name: infigratinib
Company: BridgeBio Pharma, Inc.
Treatment for: Cholangiocarcinoma of Biliary Tract

Infigratinib is an orally administered, ATP-competitive, FGFR1-3 tyrosine kinase inhibitor in development for the treatment of individuals with FGFR-driven conditions, including cholangiocarcinoma (bile duct cancer), urothelial carcinoma (bladder cancer) and achondroplasia.

Development Timeline for infigratinib

DateArticle
Dec  1, 2020BridgeBio Pharma And Affiliate QED Therapeutics Announce FDA Acceptance Of New Drug Application For Infigratinib For The Treatment Of Cholangiocarcinoma

Further information

Always consult your healthcare provider to ensure the information displayed on this page applies to your personal circumstances.